Trial of amifostine in autologous stem cell transplant

Bone Marrow Transplant. 2006 Jan;37(1):117-8. doi: 10.1038/sj.bmt.1705204.
No abstract available

Publication types

  • Clinical Trial
  • Comment
  • Comparative Study
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Amifostine / administration & dosage*
  • Amifostine / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Carmustine / administration & dosage
  • Carmustine / adverse effects
  • Child
  • Cytarabine / administration & dosage
  • Cytarabine / adverse effects
  • Female
  • Graft Survival / drug effects
  • Hodgkin Disease / blood
  • Hodgkin Disease / complications
  • Hodgkin Disease / therapy*
  • Humans
  • Male
  • Melphalan / administration & dosage
  • Melphalan / adverse effects
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / complications
  • Multiple Myeloma / therapy*
  • Podophyllotoxin / administration & dosage
  • Podophyllotoxin / adverse effects
  • Radiation-Protective Agents / administration & dosage*
  • Radiation-Protective Agents / adverse effects
  • Stem Cell Transplantation*
  • Transplantation, Homologous

Substances

  • Radiation-Protective Agents
  • Cytarabine
  • Podophyllotoxin
  • Amifostine
  • Melphalan
  • Carmustine

Supplementary concepts

  • BEAM protocol